Total Oncology — Total revenues
Gilead Sciences Total Oncology — Total revenues decreased by 3.8% to $810.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.0%, from $757.00M to $810.00M. Over 3 years (FY 2022 to FY 2025), Total Oncology — Total revenues shows an upward trend with a 14.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization of oncology therapies and growing market share in the cancer treatment space, while a decrease may signal competitive pressure or patent expirations within the oncology portfolio.
Detailed definition
This metric represents the total gross revenue generated from the sale of oncology-focused therapeutic products and trea...
Peer comparison
Comparable to oncology segment revenues reported by other large-cap biopharmaceutical companies, though variations exist based on the specific mix of hematology versus solid tumor therapies.
gild_segment_total_oncology_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $534.75M | $534.75M | $534.75M | $534.75M | $733.00M | $733.00M | $733.00M | $733.00M | $789.00M | $841.00M | $816.00M | $843.00M | $757.00M | $849.00M | $788.00M | $842.00M | $810.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +37.1% | +0.0% | +0.0% | +0.0% | +7.6% | +6.6% | -3.0% | +3.3% | -10.2% | +12.2% | -7.2% | +6.9% | -3.8% |
| YoY Change | — | — | — | — | +37.1% | +37.1% | +37.1% | +37.1% | +7.6% | +14.7% | +11.3% | +15.0% | -4.1% | +1.0% | -3.4% | -0.1% | +7.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total oncology — total revenues?
- Gilead Sciences (GILD) reported total oncology — total revenues of $810.00M in Q1 2026.
- How has Gilead Sciences's total oncology — total revenues changed year-over-year?
- Gilead Sciences's total oncology — total revenues increased by 7.0% year-over-year, from $757.00M to $810.00M.
- What is the long-term trend for Gilead Sciences's total oncology — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's total oncology — total revenues has grown at a 14.8% compound annual growth rate (CAGR), from $2.14B to $3.24B.
- What does total oncology — total revenues mean?
- The total amount of money earned from selling cancer treatment products.